Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment

• Main Authors: Xianbo Wu (Author), Yihua Xu (Author), Qi Liang (Author), Xinwei Yang (Author), Jianli Huang (Author), Jie Wang (Author), Hong Zhang (Author), Jianyou Shi (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The PI3K-Akt-mTOR pathway is a viable target for cancer treatment and can be used to treat various malignant tumours, including follicular lymphoma and breast cancer. Both enzymes, PI3K and mTOR, are critical in this pathway. Hence, in recent years, an array of inhibitors targeting these two targets...